Evidence map›Paper›PMID 42713301›Full record

ArticleIDCases2026

Reduction of immunosuppressants fails to clear hepatitis E virus infection in a heart transplant recipient.

Zihao Chen, Wenxia Niu, Guanghui Li, Xianli Chen, Shuhua Chen, Kai Zhang, Mujin Fang, Yingbin Wang, Lijuan Fu, Zizheng Zheng and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in IDCases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zihao ChenState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Department of Clinical Laboratory, Xiang'an Hospital of Xiamen University, Xiamen University, Xiamen, Fujian, PR China.
Wenxia NiuDepartment of Infectious Disease, Xiang'an Hospital of Xiamen University, Xiamen University, Xiamen, Fujian, PR China.
Guanghui LiState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Department of Clinical Laboratory, Xiang'an Hospital of Xiamen University, Xiamen University, Xiamen, Fujian, PR China.
Xianli ChenDepartment of Infectious Disease, Xiang'an Hospital of Xiamen University, Xiamen University, Xiamen, Fujian, PR China.
Shuhua ChenDepartment of Infectious Disease, Xiang'an Hospital of Xiamen University, Xiamen University, Xiamen, Fujian, PR China.
Kai ZhangDepartment of Infectious Disease, Xiang'an Hospital of Xiamen University, Xiamen University, Xiamen, Fujian, PR China.
Mujin FangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Department of Clinical Laboratory, Xiang'an Hospital of Xiamen University, Xiamen University, Xiamen, Fujian, PR China.
Yingbin WangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Department of Clinical Laboratory, Xiang'an Hospital of Xiamen University, Xiamen University, Xiamen, Fujian, PR China.
Lijuan FuDepartment of Infectious Disease, Xiang'an Hospital of Xiamen University, Xiamen University, Xiamen, Fujian, PR China.
Zizheng ZhengState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Department of Clinical Laboratory, Xiang'an Hospital of Xiamen University, Xiamen University, Xiamen, Fujian, PR China.
Ningshao XiaState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, School of Public Health, Department of Clinical Laboratory, Xiang'an Hospital of Xiamen University, Xiamen University, Xiamen, Fujian, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis E virus (HEV) infection poses a significant public health burden in immunosuppressed individuals. Here, we report a 41-year-old male patient with a history of orthotopic heart transplantation, who develop HEV genotype 4 (subtype 4d) infection one-and-a-half-year post-transplantation. The patient exhibits a very weak anti-HEV IgG response. Abnormal liver function parameters persist for one month without evidence of clinical improvement. Therefore, the immunosuppressant dosage is halved to promote effective antiviral response. The anti-HEV IgG response gradually increases; however, abnormal liver function parameters persist into the second month, and HEV infection fails to clear. The patient is administered ribavirin at a dose of 600 mg/d, and by the third month, the viral load significantly decreases. By the fourth month, HEV infection is successfully cleared, liver function parameters returned to normal, and no viral reactivation is observed through the eighth month. This work highlights therapeutic approaches for managing HEV infection in solid organ transplantation (SOT) recipients.

Indexed as

Heart transplantHepatitis E virusImmunosuppressionRibavirinViral hepatitis

Identifiers

PMID42713301
PMCPMC13551936

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.